Meling T R, Nylén E S
Kjevekirurgisk avdeling, Ullevål sykehus, Oslo.
Tidsskr Nor Laegeforen. 1996 Nov 30;116(29):3476-80.
Growth hormone (GH) has been in clinical use for almost 40 years to promote linear growth in growth hormone deficient children. Treatment has usually been stopped after the epiphyseal plates have fused or when the person reaches a proper height. Previously, GH replacement therapy in adults was not deemed clinically indicated. GH-deficiency in adults is now accepted as a clinical entity, manifested by cardiovascular dysfunction, dyslipidemia, reduced capacity for exercise and muscular weakness, altered body composition, increased prevalence of osteoporosis, and impaired psychological well-being. The treatment of adults used to be unrealistic, because of the limited supply of human pituitary-derived GH. Moreover, the risk of transferring Creutzfeldt-Jakobs disease led to a stop in the therapeutic use of pituitary GH preparations. The availability of recombinant human prion-free GH has made replacement therapy possible in GH-deficient adults. In this review, the GH deficiency syndrome in adults is described, together with the results of recent clinical studies of GH replacement treatment in adults.
生长激素（GH）已在临床应用近40年，用于促进生长激素缺乏儿童的线性生长。通常在骨骺板融合后或患者达到适当身高时停止治疗。以前，成人生长激素替代疗法在临床上被认为没有指征。成人生长激素缺乏现在被公认为一种临床病症，表现为心血管功能障碍、血脂异常、运动能力下降和肌肉无力、身体成分改变、骨质疏松患病率增加以及心理健康受损。由于人垂体来源的生长激素供应有限，成人的治疗曾经不切实际。此外，传播克雅氏病的风险导致垂体生长激素制剂的治疗用途停止。重组无朊病毒人生长激素的可获得性使生长激素缺乏成人的替代疗法成为可能。在这篇综述中，描述了成人生长激素缺乏综合征以及成人生长激素替代治疗的近期临床研究结果。
